New Science: Chemical Profile and Clinical Efficacy of Micro-Fragmented Adipose-derived MSC Therapy (MFAT) in the Treatment of Knee Osteoarthritis.

Check out the new article by long-time TOBI faculty, Dr. Gerard Malanga, published in Biologic Orthopedic Journal.

By the year 2040, it is estimated that 25% of adults in the US will be diagnosed with osteoarthritis by a physician.  Osteoarthritis, considered as a progessive joint disorder due to “wear and tear,” has been described by researchers to involve a complex dynamic of pro-inflammatory mediators leading to an increase of enzymes that degrade soft-tissue supporting the joint. This article looks at the chemical composition of Adipose-derived MSCs, and the use of anti-inflammatory properties there within, to combat the progression of tissue degradation in knee osteoarthritis.  Micro-fragmented Adipose tissue versus Enzyme-Processed Adipose tissue is further evaluated with respect to the biochemical profile of Adipose-derived MSCs for clinical efficacy in the treatment of knee osteoarthritis. After injection, a variety of bioactive molecules and cell markers initiate and promote cell-signaling mechanisms to transport cellular proteins and genetic information. This article provides a table summary of the biochemical profile of AD-MSCs.

In conclusion, a substantial body of research suggests that AD-MSC therapy has a well-documented immune-modulating role in delaying or preventing the onset of end-stage knee osteoarthritis. Congratulations to TOBI faculty Dr. Malanga for his contribution to this study published in the Biologic Orthopedic Journal. Download the full article here

This field is for validation purposes and should be left unchanged.

Get on the path to comprehensive healing and long-term pain relief today.

Accessibility Toolbar

Request an Appointment
Scroll to Top